Therapeutic impact of rHuEPO on abnormal platelet APP, BACE 1, presenilin 1, ADAM 10 and Aβ expressions in chronic kidney disease patients with cognitive dysfunction like Alzheimer's disease: A pilot study

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Vinothkumar GVenkataraman P

Abstract

Cognitive dysfunction is reported to be a major cause of morbidity in chronic kidney disease (CKD). The senile plaques (SPs) in the brain are one of the most pathophysiological characteristics of cognitive dysfunction and its major constituent amyloid β (Aβ) released from amyloid precursor protein (APP) by β (BACE1) and γ (presenilin 1) secretases . Platelets contain more than 95% of the circulating APP and implicate as a candidate biomarker for cognitive decline. Recombinant human erythropoietin (rHuEPO) is a standard therapy for anemia in CKD and also acts as a neuroprotective agent. The aim of the study is to determine the impact of rHuEPO therapy on platelet APP processing in CKD with Cognitive Dysfunction. A total of 60 subjects comprising of 30 CKD without cognitive dysfunction and 30 CKD with cognitive dysfunction based on neuropsychological assessment. APP, BACE1, Presenilin 1, ADAM 10 (α secretase) and Aβ expressions in platelets were determined by western blotting and lipid peroxidation (LPO) in platelet rich plasma (PRP) was done by spectrophotometrically. The parameters were statistically compared with Alzheimer's disease (AD), Normocytic normochromic anemic and healthy subjects. Significantly (p < 0.05) decreased A...Continue Reading

References

May 29, 1987·Biochemical and Biophysical Research Communications·T P Devasagayam, U Tarachand
Aug 4, 1995·Biochemical and Biophysical Research Communications·M ChenH L Fernandez
Dec 1, 1995·Journal of the Neurological Sciences·G FazekasG J Krejs
Jul 1, 1997·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·A R SehgalP J Whitehouse
Jun 3, 1999·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J L PickettA R Nissenson
Jun 17, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Francesco LocatelliCarmine Zoccali
Jul 24, 2004·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·Cynthia A RiccioJeremy R Sullivan
Jun 2, 2005·Neurotoxicology·Stefano BartesaghiBarbara Viviani
Sep 6, 2005·Clinica Chimica Acta; International Journal of Clinical Chemistry·Vincenzo SolfrizziFrancesco Panza
Nov 1, 2005·Journal of the Neurological Sciences·Kun TangRoger N Rosenberg
Mar 15, 2006·Kidney & Blood Pressure Research·Werner SiemsHannelore Hampl
Dec 19, 2006·Neurobiology of Aging·J A JohnstonA P Passmore
Nov 21, 2007·Kidney International. Supplement·P KatavetinM Nangaku
Apr 18, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Tracy McGowanMarsha Wolfson
Nov 27, 2008·Kidney International. Supplement·Victoria CachofeiroJosé Luño
Jan 28, 2009·Platelets·Christopher C T SmithMichael B Cooper
Aug 25, 2009·Experimental Gerontology·Barbara BorroniAlessandro Padovani
Oct 8, 2009·Clinical Journal of the American Society of Nephrology : CJASN·Pablo E PergolaPeter Bowers
Dec 5, 2009·Critical Reviews in Clinical Laboratory Sciences·Sudarsan KrishnaswamyRalph N Martins
Jul 26, 2011·Biochemical Pharmacology·S ChateauvieuxM Diederich
Oct 18, 2011·Neurotoxicity Research·Elena TamagnoMassimo Tabaton
Jan 21, 2012·Journal of Sport & Exercise Psychology·Yu-Kai ChangJennifer L Etnier
Sep 1, 2012·Journal of the American Society of Nephrology : JASN·Jodie L Babitt, Herbert Y Lin
Mar 5, 2013·Trends in Pharmacological Sciences·Haibo WangYong Shen
Apr 12, 2013·Neurochemical Research·Paloma Bermejo-BescósAngel María Villar
Mar 4, 2014·Kidney International·David A Drew, Daniel E Weiner
Apr 29, 2014·Neuropharmacology·Marta RuizMinerva Giménez Y Ribotta
Jul 24, 2014·Jornal brasileiro de nefrologia : ʹorgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia·Sílvia Mendonça da MattaAna Cristina Simões E Silva
Jul 30, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Ranganathan SrinivasanPrabal K Manna

❮ Previous
Next ❯

Citations

Oct 20, 2019·Basic & Clinical Pharmacology & Toxicology·Mi Ran ChoiDai-Jin Kim
Apr 5, 2020·Metabolic Brain Disease·Chun-Yun ZhangXian-Fang Meng
Apr 3, 2020·Nature Reviews. Nephrology·Davide ViggianoGiovambattista Capasso
Aug 14, 2020·International Journal of Molecular Sciences·Vince SzegeczkiTamás Juhász

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.